Section
A large-scale cohort study of 47,365 head and neck cancer patients reveals a significant market shift toward pembrolizumab and a 41.2% incidence of immune-related adverse events, though severe toxicities remain rare and are linked to specif
A multicenter randomized clinical trial demonstrates that selective calcium supplementation based on early postoperative PTH levels is as effective as routine prophylaxis in preventing hypocalcemia after total thyroidectomy, offering a stra
A systematic review and meta-analysis of over 400,000 patients reveals that while older adults face higher relative risks for nerve injury and hematoma following thyroidectomy, the absolute risk remains low, confirming the procedure’s
A secondary analysis of the CAPTAIN-1st trial reveals that adding camrelizumab to first-line chemotherapy significantly improves five-year overall survival in RM-NPC, with a 37.8% survival rate and notable benefits linked to rapid EBV DNA c
This article examines the clinical accuracy of Sentinel Lymph Node Biopsy for head and neck Merkel cell carcinoma, highlighting a significant false-negative rate and identifying risk factors that necessitate more personalized treatment stra
This systematic review and network meta-analysis of 52 randomized trials evaluates pharmacological agents for controlled hypotension in ESS, identifying diltiazem, esmolol, and dexmedetomidine as the most effective for reducing intraoperati
A case-control study comparing IMPT and IMRT for nasopharyngeal carcinoma shows that IMPT significantly reduces grade 2+ acute toxicities without compromising long-term survival or local-regional control, suggesting a superior therapeutic i
Researchers have developed a 4-level classification system using routine audiometric data to estimate cochlear implant candidacy likelihood. This tool moves beyond traditional binary screening, providing a probability gradient that enhances
The MIST+ trial demonstrates that intranasal saline is as effective as mometasone for pediatric sleep-disordered breathing, suggesting a conservative 3-month saline trial can resolve symptoms in half of patients and potentially reduce the n
A new study reveals that ‘tumor-informed’ blood tests can detect recurring head and neck cancer months before traditional scans, offering a critical window for intervention in high-risk patients.
A landmark systematic review of over 48,000 patients reveals that while the proportion of AIFRS in immunocompromised populations is increasing, mortality rates have dropped significantly since 2013 due to diagnostic and therapeutic advancem
A comprehensive meta-analysis reveals that while the proportion of AIFRS in immunocompromised patients has risen to 16.6% in recent years, mortality has significantly decreased to 28.2% due to improved diagnostic and therapeutic strategies.
Researchers have validated a Hebrew version of the ‘Sniffin’ Sticks’ identification test, providing a highly reliable and culturally adapted tool for diagnosing olfactory dysfunction in Israel with a sensitivity of 93.3%.
Researchers have developed a rapid, 5-item mobile application-based test to screen for olfactory dysfunction, offering a high-accuracy, low-cost alternative to traditional diagnostic methods for a condition often linked to aging and neurolo
A landmark Phase 3 trial establishes Intensity-Modulated Proton Therapy (IMPT) as a new standard for oropharyngeal cancer, demonstrating non-inferior progression-free survival, significantly improved overall survival, and a marked reduction
Research identifies postoperative lymphatic exudate as a superior source of ctDNA for detecting molecular residual disease in HPV-independent head and neck cancer. This proximal liquid biopsy significantly outperforms plasma in predicting l
A Phase II clinical trial demonstrates that combining tislelizumab with neoadjuvant chemotherapy significantly improves pathological response rates and organ preservation in patients with locally advanced head and neck squamous cell carcino
Recent clinical trials reveal that LBL-007, a novel anti-LAG-3 antibody, significantly enhances treatment outcomes for advanced nasopharyngeal carcinoma when combined with PD-1 inhibitors, marking a potential shift in the standard of care f
A multi-center phase II trial demonstrates that mid-treatment FDG-PET imaging can safely identify patients with HPV+ oropharyngeal cancer for radiation dose reduction, resulting in non-inferior tumor control and significantly improved quali
This Phase II trial demonstrates that combining nivolumab with carboplatin and paclitaxel as neoadjuvant therapy for SCCHN achieves a 45% pathologic complete response rate and high 3-year survival, offering a promising strategy for locally
